TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30916028

Group type: EXPERIMENTAL
Intervention: FiO2 100%
Number of subjects: 58

Group type: COMPARATOR
Intervention: FiO2 80%
Number of subjects: 58
Study: 29613826

Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis (DTS)
Number of subjects: 125
Study: 27266443

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active Control Training (CT)
Number of subjects: 0
Study: 24485487

Group type: EXPERIMENTAL
Intervention: 1μg of cosyntropin administered intravenously
Number of subjects: 45
Study: 22894958

Group type: EXPERIMENTAL
Intervention: CYD-TDV (tetravalent dengue vaccine)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control vaccine (placebo for first dose, licensed hepatitis-A for children, influenza vaccine for adolescents and adults)
Number of subjects: 1200
Study: 19876613

Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Presence of the metabolic syndrome
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Use of amlodipine
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Family history of diabetes
Number of subjects: 4449

Group type: EXPERIMENTAL
Intervention: Family history of cardiovascular disease
Number of subjects: 4449
Study: 17662087

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15761089

Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure (LBNP) -20 mmHg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower Body Negative Pressure (LBNP) -40 mmHg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Head-Up Tilt (HUT)
Number of subjects: 10
Study: 12038948

Group type: EXPERIMENTAL
Intervention: 30 mg of cevimeline 3 times daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 60 mg of cevimeline 3 times daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 10385778

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Amiodarone with beta-blockade
Number of subjects: 143

Group type: COMPARATOR
Intervention: Other patients (without beta-blockade)
Number of subjects: 143
Study: 8529717

Group type: EXPERIMENTAL
Intervention: Covert monitoring of inhalation
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Theophylline treatment (open randomized trial)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Physician prescribed doses of theophylline
Number of subjects: 89
Study: 2224293

Group type: EXPERIMENTAL
Intervention: Active fitting (AF) programme of hearing aids
Number of subjects: 128
Study: 392005

Group type: EXPERIMENTAL
Intervention: Impulsin (N-2-hydroxyethyl palmitamide)
Number of subjects: 1864
Study: 31162376

Group type: EXPERIMENTAL
Intervention: Conventional drainage seton
Number of subjects: 60

Group type: COMPARATOR
Intervention: External anal sphincter-sparing seton
Number of subjects: 60
Study: 28920540

Group type: COMPARATOR
Intervention: Conventional module ligation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Figure-of-eight module ligation
Number of subjects: 120
Study: 26052069

Group type: EXPERIMENTAL
Intervention: Patients with moderate hip osteoarthritis walking on a treadmill with increasing speeds.
Number of subjects: 36
Study: 23640485

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 20662976

Group type: EXPERIMENTAL
Intervention: CTI + PV isolation (PVI) (Group B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CTI ablation (Group A)
Number of subjects: 48
Study: 19639058

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.3 mg/mL) with freeze-dried bone allograft (FDBA; group A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft (ABBG; group B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB (0.3 mg/mL) with anorganic bovine bone graft/mineralized collagen bone substitute (ABBG/MCBS; group C)
Number of subjects: 12
Study: 17371357

Group type: EXPERIMENTAL
Intervention: Topiramate (50 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lamotrigine (50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15234287

Group type: EXPERIMENTAL
Intervention: Group N Trial (new subfoveal CNV)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Group B Trial (predominantly hemorrhagic CNV)
Number of subjects: 789
Study: 11576883

Group type: EXPERIMENTAL
Intervention: 4 microg of paricalcitol intravenously with the hemodialysis session three times weekly for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 31
Study: 9305517

Group type: EXPERIMENTAL
Intervention: Randomized start design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized withdrawal design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological markers using neuroimaging or other measures
Number of subjects: 0
Study: 7870844

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MCPP (0.5 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alprazolam + MCPP
Number of subjects: 10
Study: 2680231

Group type: EXPERIMENTAL
Intervention: Intravenous injection of [1-13C]leucine (0.05 g/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous injection of unlabelled leucine (4 g)
Number of subjects: 10
Study: 767080

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dysphoric responders
Number of subjects: 0
Study: 31654593

Group type: EXPERIMENTAL
Intervention: ED-AKI patients
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Progression of AKI stage
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: ED-AKI patients discharged from hospital
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: ED-AKI patients at 90-days post-discharge
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: ED-AKI patients at 12 months post-discharge
Number of subjects: 572
Study: 30317381

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 349

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 349
Study: 27637753

Group type: EXPERIMENTAL
Intervention: Provox FreeHands FlexiVoice
Number of subjects: 40
Study: 26100988

Group type: EXPERIMENTAL
Intervention: Ischemia‐Modified Albumin (IMA) levels in the AP group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amylase levels in the AP group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (Sham)
Number of subjects: 16
Study: 24156204

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 8% arginine, calcium carbonate, and 1,000 ppm MFP (Colgate Sensitive Pro‐Relief)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Commercially available fluoride dentifrice (Colgate Cibaca)
Number of subjects: 100
Study: 21474474

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg before operation and 75 mg twice daily for 5 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19347770

Group type: EXPERIMENTAL
Intervention: FOS and fibre-enriched tube feeding
Number of subjects: 19

Group type: COMPARATOR
Intervention: No residue tube feeding (non-FOS group)
Number of subjects: 19
Study: 22648123

Group type: EXPERIMENTAL
Intervention: Hybrid transvaginal NOTES (TV group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hybrid transumbilical NOTES (TU group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL group)
Number of subjects: 60
Study: 16272755

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specific drugs not mentioned)
Number of subjects: 0
Study: 12625832

Group type: EXPERIMENTAL
Intervention: 34 energy% (E%) fat meal
Number of subjects: 26

Group type: COMPARATOR
Intervention: 20 energy% (E%) fat meal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3 energy% (E%) fat meal
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) administration
Number of subjects: 26
Study: 10550466

Group type: EXPERIMENTAL
Intervention: 2.5 mg/day alendronate
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: 5 mg/day alendronate
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 8526832

Group type: EXPERIMENTAL
Intervention: High altitude acclimatization (HA) for 16 days followed by reexposure (RA) for 30 hours at 4300 m
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Reexposure to high altitude (RA) after acclimatization
Number of subjects: 6
Study: 2081141

Group type: EXPERIMENTAL
Intervention: Felodipine ER 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine ER 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine ER 20 mg and 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg, 20 mg, and 40 mg
Number of subjects: 0
Study: 120549

Group type: EXPERIMENTAL
Intervention: Deanol (900 mg/day for 21 days)
Number of subjects: 0
Study: 11159568

Group type: EXPERIMENTAL
Intervention: Agnus castus (dry extract tablets) one tablet daily for three consecutive cycles
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Agnus castus (dry extract tablets)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 30651139

Group type: EXPERIMENTAL
Intervention: Manual acupuncture plus electroacupuncture (EA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham acupuncture plus placebo EA without electrical stimulation
Number of subjects: 68
Study: 29554012

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonexercise Control (Con)
Number of subjects: 36
Study: 27513088

Group type: EXPERIMENTAL
Intervention: PCOMS Full
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Outcome Rating Scale (ORS)-only
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Session Rating Scale (SRS)-only
Number of subjects: 94
Study: 24724771

Group type: EXPERIMENTAL
Intervention: Rice starch prethickened lactose-free milk protein-based infant formula
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard lactose-containing milk-based infant formula (control)
Number of subjects: 132
Study: 22613545

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irbesartan 150 mg/d and 300 mg/d
Number of subjects: 0
Study: 20434961

Group type: EXPERIMENTAL
Intervention: 900 mg/d of DHA orally for 24 weeks
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study: 17274711

Group type: EXPERIMENTAL
Intervention: EMD + ACBP
Number of subjects: 27

Group type: COMPARATOR
Intervention: EMD
Number of subjects: 27
Study: 16375040

Group type: EXPERIMENTAL
Intervention: Personalised letter
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Personalised letter plus brochure
Number of subjects: 1322
Study: 12064984

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 10208225

Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg daily)
Number of subjects: 12
Study: 7842188

Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid 25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid 50 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 8
Study: 2220345

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice daily for 2 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo tablets 1 tablet twice daily for 2 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study: 30019617

Group type: EXPERIMENTAL
Intervention: Heading group (n = 18)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Kicking-control group (n = 16)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Heading group at 24 h post-heading
Number of subjects: 37

Group type: COMPARATOR
Intervention: Heading group vs Kicking-control group at 24 h post-heading
Number of subjects: 37
Study: 28432894

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) treatment for OCD, PD/A, SAD, and GAD
Number of subjects: 0
Study: 25921948

Group type: EXPERIMENTAL
Intervention: Histidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22996743

Group type: EXPERIMENTAL
Intervention: Impact + resistance training (POWIR)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Exercise placebo (FLEX)
Number of subjects: 71
Study: 22192583

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (50 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 0
Study: 20180667

Group type: EXPERIMENTAL
Intervention: Pregnant opioid dependent patients (N = 108)
Number of subjects: 108

Group type: COMPARATOR
Intervention: General pregnant patients (N = 1,516)
Number of subjects: 108
Study: 17022356

Group type: EXPERIMENTAL
Intervention: RPRS intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Informational control (IC)
Number of subjects: 34
Study: 14674905

Group type: EXPERIMENTAL
Intervention: Five times weekly application of short-contact dithranol (SCD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Three times weekly application of short-contact dithranol (SCD)
Number of subjects: 25
Study: 10505482

Group type: EXPERIMENTAL
Intervention: Sulpiride (150‐300 mg)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 9069860

Group type: EXPERIMENTAL
Intervention: Acupressure (treatment group, n = 30) with bilateral elastic bands exerting pressure on the wrist during the perioperative period.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Placebo (placebo group, n = 30) with elastic bands incapable of acupressure placed on wrists.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (n = 30) receiving routine nursing and medical interventions for nausea and vomiting.
Number of subjects: 90
Study: 1890788

Group type: EXPERIMENTAL
Intervention: HL condition (high and low self-esteem children viewing both high and low SR criterion models)
Number of subjects: 48

Group type: COMPARATOR
Intervention: M condition (high and low self-esteem children viewing only a middle SR criterion model)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HL condition (low self-esteem group)
Number of subjects: 48
Study: 6187310

Group type: EXPERIMENTAL
Intervention: High-dose gestagen therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Chemotherapy (cyclophosphamide, 5-fluorouracil, methotrexate, vinblastine)
Number of subjects: 69
Study: 31971811

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (six sessions including baseline assessment, diaphragmatic breath training, and biofeedback screens)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 104
Study: 30672381

Group type: EXPERIMENTAL
Intervention: MARTAS intervention (up to 6 individual-level sessions with a linkage coordinator over 90 days)
Number of subjects: 22
Study: 28131423

Group type: EXPERIMENTAL
Intervention: Preoperative use of angiotensin receptor blockers (ARBs)
Number of subjects: 1351

Group type: COMPARATOR
Intervention: No renin-angiotensin-system inhibitors
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors (ACEis)
Number of subjects: 1351
Study: 27318344

Group type: EXPERIMENTAL
Intervention: Sustained Inflation (SI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Progressively Increased Positive End Expiratory Pressure (IP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV)
Number of subjects: 32
Study: 23617767

Group type: EXPERIMENTAL
Intervention: Supervised exercise training program (3 hours a week for 10 weeks) in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 20733014

Group type: EXPERIMENTAL
Intervention: Prevention group (expressive writing + psycho-education)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (non-treatment)
Number of subjects: 359
Study: 19542793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 252
Study: 16517548

Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 42283

Group type: COMPARATOR
Intervention: Control group (not screened)
Number of subjects: 42283
Study: 12527544

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for generalized anxiety disorder in primary care (CBT‐GAD/PC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 12
Study: 10664917

Group type: EXPERIMENTAL
Intervention: Celecoxib (600 mg bid)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naproxen (500 mg bid)
Number of subjects: 24
Study: 9769898

Group type: EXPERIMENTAL
Intervention: Fast release tablet (FR 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fast-slow release tablet (FSR 150 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular solution (i.m. 100 mg) at 8 a.m. and 8 p.m. and 1 p.m.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fast release tablet (FR 100 mg) vs Fast-slow release tablet (FSR 150 mg)
Number of subjects: 12
Study: 7801652

Group type: EXPERIMENTAL
Intervention: Active exploration (blindfolded, exploring real objects with hands)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor encoding (adequate hand movements without sensory contact)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive touch (no hand movements, based on sensory impressions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensory encoding (passive touch at both encoding and test)
Number of subjects: 0
Study: 3294190

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (30-90 mg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Indoramin (75-225 mg daily)
Number of subjects: 17
Study: 29905004

Group type: EXPERIMENTAL
Intervention: 3D gamma passing rates (%GPs) with 3%/3 mm criterion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2D gamma passing rates (%GPs) with 3%/3 mm criterion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PTV-specific 2D %GP gradient
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PTV-specific 3D %GP gradient
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 2D and 3D %GPs correlation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Whole-body %GP with 3%/3 mm criterion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PTV-specific gamma evaluation
Number of subjects: 11
Study: 28185274

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26409409

Group type: EXPERIMENTAL
Intervention: Anodal stimulation to the non-dominant motor cortex
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Anodal stimulation to the dominant motor cortex
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 34
Study: 24496201

Group type: EXPERIMENTAL
Intervention: High-cut-off (HCO) membranes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional high-flux (PF) membranes
Number of subjects: 12
Study: 21929768

Group type: EXPERIMENTAL
Intervention: Vigorous Intensity High Dose Exercise Augmentation (DEI)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Health Education Intervention Augmentation (HEI)
Number of subjects: 330
Study: 18356552

Group type: EXPERIMENTAL
Intervention: B‐vitamins (folic acid 2 mg, vitamin B6 25 mg, and vitamin B12 0.5 mg)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 17162709

Group type: EXPERIMENTAL
Intervention: Intranasal E2 (n = 16)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Raloxifene (n = 19)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 46
Study: 12070631

Group type: EXPERIMENTAL
Intervention: Hypoxic group (intermittent hypoxic exposure for 1 week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups (hypoxic and control)
Number of subjects: 14
Study: 10445623

Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.2 parts per million)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 13
Study: 7756073

Group type: EXPERIMENTAL
Intervention: Active compression‐decompression cardiopulmonary resuscitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional cardiopulmonary resuscitation
Number of subjects: 36
Study: 1964962

Group type: EXPERIMENTAL
Intervention: Thiotepa and Etoposide (total dose: Thiotepa 600-900 mg/M2 over 3 days, Etoposide 1500 mg/M2 over 3 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thiotepa, Etoposide and BCNU (total dose: BCNU 600 mg/M2 over 4 days)
Number of subjects: 10
Study: 504040

Group type: EXPERIMENTAL
Intervention: Tienilic acid 250 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 650 mg (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 0